Drug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration

• DOI: 10.1007/s00018-019-03283-2
• Publication Date: 2019-08-26T09:02:38Z
• Authors: Ayse Sahaboglu; Maria Miranda; Denis Canjuga; Meltem Avci-Adali; Natalia Savytska; Enver Secer; Jessica Abigail F...; Gülru Kayık; Serdar Durdagi
• Keywords: 0301 basic medicine; 570; pathology [Retinal Degeneration]; therapeutic use [Phthalazines]; 3-aminobenzamide; 610; Poly(ADP-ribose) Polymerase Inhibitors; talazoparib; Retina; therapeutic use [Benzamides]; Mice; 03 medical and health sciences; Animals; Humans; ddc:610; methods [Drug Repositioning]; drug effects [Retina]; metabolism [Poly(ADP-ribose) Polymerases]; drug therapy [Retinal Degeneration]; metabolism [Retinal Degeneration]; therapeutic use [Poly(ADP-ribose) Polymerase Inhibitors]; Retinal Degeneration; Drug Repositioning; pathology [Retinitis Pigmentosa]; pathology [Retina]; 3. Good health; metabolism [Retinitis Pigmentosa]; Benzamides; Phthalazines; Poly(ADP-ribose) Polymerases; drug therapy [Retinitis Pigmentosa]; Retinitis Pigmentosa; metabolism [Retina]

The enzyme poly-ADP-ribose-polymerase (PARP) has important roles for many forms of DNA repair and it also participates in transcription, chromatin remodeling and cell death signaling. Currently, some PARP inhibitors are approved for cancer therapy, by means of canceling DNA repair processes and cell division. Drug repurposing is a new and attractive aspect of therapy development that could offer low-cost and accelerated establishment of new treatment options. Excessive PARP activity is also involved in neurodegenerative diseases including the currently untreatable and blinding retinitis pigmentosa group of inherited retinal photoreceptor degenerations. Hence, repurposing of known PARP inhibitors for patients with non-oncological diseases might provide a facilitated route for a novel retinitis pigmentosa therapy. Here, we demonstrate and compare the efficacy of two different PARP inhibitors, BMN-673 and 3-aminobenzamide, by using a well-established retinitis pigmentosa model, the rd1 mouse. Moreover, the mechanistic aspects of the PARP inhibitor-induced protection were also investigated in the present study. Our results showed that rd1 rod photoreceptor cell death was decreased by about 25-40% together with the application of these two PARP inhibitors. The wealth of human clinical data available for BMN-673 highlights a strong potential for a rapid clinical translation into novel retinitis pigmentosa treatments. Remarkably, we have found that the efficacy of 3 aminobenzamide was able to decrease PARylation at the nanomolar level. Our data also provide a link between PARP activity with the Wnt/β-catenin pathway and the major intracellular antioxidant concentrations behind the PARP-dependent retinal degeneration. In addition, molecular modeling studies were integrated with experimental studies for better understanding of the role of PARP1 inhibitors in retinal degeneration.